Purpose: To evaluate the value and diagnostic performance of virtual touch tissue imaging quantification (VTIQ) and to determine the optimum cut-off value for differential diagnosis between benign and malignant breast lesions.
Methods: Conventional ultrasonography (US) and VTIQ were performed in 454 patients with 466 breast lesions with a Siemens Acuson S3000 ultrasound machine. All lesions were assessed by an ultrasound Breast Imaging Reporting and Data System (BI-RADS) and confirmed by histopathology. The maximum, mean, and minimum shear wave velocity (SWV) values were quantitatively measured in m/s within the regions of interest (ROIs) and ranged from 0.5 to 10 m/s. The sensitivity, specificity, accuracy, and area under the receiver operating curve (AUC) of the VTIQ, BI-RADS, and combined data were compared.
Results: Among the 466 breast lesions, 266 were benign and 200 were malignant. All of the SWV values of the malignant lesions were significantly greater than those of the benign ones (P < 0.05). The optimal cut-off values for SWVmax, SWVmin, SWVmean, and SWVmax/SWVmin obtained from ROC analysis were 5.37 m/s, 3.08 m/s, 4.04 m/s, and 1.83, respectively. Logistic regression analysis revealed that BI-RADS was an independent risk factor for the differential diagnosis of breast lesions, whereas SWV values were not independent risk factors.
Conclusions: VTIQ is useful in the differential diagnosis between benign and malignant breast lesions. The combination of VTIQ and ultrasonic BI-RADS can improve the diagnostic performance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10396-019-00948-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Innovative strategies for minimizing hematoma risk in MRI-guided breast biopsies.
Radiol Oncol
January 2025
1Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Bern,
Background: The study aimed to investigate the reduction of hematoma risk during MRI-guided breast biopsies by evaluating position-dependent intervention parameters and characteristics of the target lesion.
Materials And Methods: We retrospectively analyzed 252 percutaneous MRI-guided breast biopsies performed at a single center between January 2013 and December 2023. Two groups were built depending on the severity of relative hematoma formation (using a cut-off ≤ 7.
Evaluating the correlation between pretreatment F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival.
Pathol Oncol Res
January 2025
Department of Nuclear Medicine, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, Istanbul, Türkiye.
Background And Objectives: This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.
Methods: We retrospectively analyzed data from 100 females with stage 2-4 NLBC who underwent pretreatment F-FDG Positron emission tomography-computed tomography (PET/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated.
Ultrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer.
Front Oncol
January 2025
Department of Radiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: In the realm of breast cancer diagnosis and treatment, accurately discerning molecular subtypes is of paramount importance, especially when aiming to avoid invasive tests. The updated guidelines for diagnosing and treating HER2 positive advanced breast cancer, as presented at the 2021 National Breast Cancer Conference and the Annual Meeting of the Chinese Society of Clinical Oncology, highlight the significance of this approach. A new generation of drug-antibody combinations has emerged, expanding the array of treatment options for HER2 positive advanced breast cancer and significantly improving patient survival rates.
View Article and Find Full Text PDFBreast Suspicious Microcalcifications on Contrast-Enhanced Mammograms: Practice and Reflection.
Int J Gen Med
January 2025
Department of Radiology, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, People's Republic of China.
Purpose: To evaluate the use of contrast enhanced mammography (CEM) in suspicious microcalcifications and to discuss strategies to cope with its diagnostic limitations.
Methods: We retrospectively evaluated patients with suspicious calcifications who underwent CEM at our institution. We collected and analyzed morphological findings, enhancement patterns and pathological findings of suspicious microcalcifications on CEM.
Image-guided biopsy of clinically occult nipple lesions: techniques and learning points.
Quant Imaging Med Surg
January 2025
Department of Radiology, Changi General Hospital, Singapore, Singapore.
Percutaneous biopsy is the standard of care for breast lesions, except nipple lesions which are primarily biopsied by excision due to perceived risks of pain and bleeding. However, excisional biopsy of nipple lesion inevitably leads to disfigurement and possible loss of the nipple-areolar complex (NAC), highlighting the need for minimally invasive biopsy techniques. We present our experience of seven patients who underwent ultrasound-guided core biopsy or vacuum-assisted biopsy (VAB) for sampling of clinically occult nipple lesions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!